64 related articles for article (PubMed ID: 28566721)
21. CXCL12 loaded-dermal filler captures CXCR4 expressing melanoma circulating tumor cells.
Ieranò C; D'Alterio C; Giarra S; Napolitano M; Rea G; Portella L; Santagata A; Trotta AM; Barbieri A; Campani V; Luciano A; Arra C; Anniciello AM; Botti G; Mayol L; De Rosa G; Pacelli R; Scala S
Cell Death Dis; 2019 Jul; 10(8):562. PubMed ID: 31332163
[TBL] [Abstract][Full Text] [Related]
22. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells.
Murakami T; Maki W; Cardones AR; Fang H; Tun Kyi A; Nestle FO; Hwang ST
Cancer Res; 2002 Dec; 62(24):7328-34. PubMed ID: 12499276
[TBL] [Abstract][Full Text] [Related]
23. CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis.
Ieranò C; Portella L; Lusa S; Salzano G; D'Alterio C; Napolitano M; Buoncervello M; Macchia D; Spada M; Barbieri A; Luciano A; Barone MV; Gabriele L; Caraglia M; Arra C; De Rosa G; Scala S
Nanoscale; 2016 Apr; 8(14):7562-71. PubMed ID: 26983756
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic targeting and rapid mobilization of endosteal HSC using a small molecule integrin antagonist.
Cao B; Zhang Z; Grassinger J; Williams B; Heazlewood CK; Churches QI; James SA; Li S; Papayannopoulou T; Nilsson SK
Nat Commun; 2016 Mar; 7():11007. PubMed ID: 26975966
[TBL] [Abstract][Full Text] [Related]
25. A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion.
Fontanella R; Pelagalli A; Nardelli A; D'Alterio C; Ieranò C; Cerchia L; Lucarelli E; Scala S; Zannetti A
Cancer Lett; 2016 Jan; 370(1):100-7. PubMed ID: 26517945
[TBL] [Abstract][Full Text] [Related]
26. CXCR4-targeted near-infrared imaging allows detection of orthotopic and metastatic human osteosarcoma in a mouse model.
Guan G; Lu Y; Zhu X; Liu L; Chen J; Ma Q; Zhang Y; Wen Y; Yang L; Liu T; Wang W; Ran H; Qiu X; Ke S; Zhou Y
Sci Rep; 2015 Oct; 5():15244. PubMed ID: 26472699
[TBL] [Abstract][Full Text] [Related]
27. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
Scala S
Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
[TBL] [Abstract][Full Text] [Related]
28. Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancer.
Cioffi M; D'Alterio C; Camerlingo R; Tirino V; Consales C; Riccio A; Ieranò C; Cecere SC; Losito NS; Greggi S; Pignata S; Pirozzi G; Scala S
Sci Rep; 2015 May; 5():10357. PubMed ID: 26020117
[TBL] [Abstract][Full Text] [Related]
29. CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks.
Guo F; Wang Y; Liu J; Mok SC; Xue F; Zhang W
Oncogene; 2016 Feb; 35(7):816-26. PubMed ID: 25961926
[TBL] [Abstract][Full Text] [Related]
30. T cell exclusion, immune privilege, and the tumor microenvironment.
Joyce JA; Fearon DT
Science; 2015 Apr; 348(6230):74-80. PubMed ID: 25838376
[TBL] [Abstract][Full Text] [Related]
31. CXCR4 over-expression and survival in cancer: a system review and meta-analysis.
Zhao H; Guo L; Zhao H; Zhao J; Weng H; Zhao B
Oncotarget; 2015 Mar; 6(7):5022-40. PubMed ID: 25669980
[TBL] [Abstract][Full Text] [Related]
32. A critical role of Src family kinase in SDF-1/CXCR4-mediated bone-marrow progenitor cell recruitment to the ischemic heart.
Cheng M; Huang K; Zhou J; Yan D; Tang YL; Zhao TC; Miller RJ; Kishore R; Losordo DW; Qin G
J Mol Cell Cardiol; 2015 Apr; 81():49-53. PubMed ID: 25655934
[TBL] [Abstract][Full Text] [Related]
33. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
[TBL] [Abstract][Full Text] [Related]
34. Advances in stem cell mobilization.
Hopman RK; DiPersio JF
Blood Rev; 2014 Jan; 28(1):31-40. PubMed ID: 24476957
[TBL] [Abstract][Full Text] [Related]
35. Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases.
Portella L; Vitale R; De Luca S; D'Alterio C; Ieranò C; Napolitano M; Riccio A; Polimeno MN; Monfregola L; Barbieri A; Luciano A; Ciarmiello A; Arra C; Castello G; Amodeo P; Scala S
PLoS One; 2013; 8(9):e74548. PubMed ID: 24058588
[TBL] [Abstract][Full Text] [Related]
36. Molecular imaging of chemokine receptor CXCR4.
Weiss ID; Jacobson O
Theranostics; 2013; 3(1):76-84. PubMed ID: 23382787
[TBL] [Abstract][Full Text] [Related]
37. In vivo self-bio-imaging of tumors through in situ biosynthesized fluorescent gold nanoclusters.
Wang J; Zhang G; Li Q; Jiang H; Liu C; Amatore C; Wang X
Sci Rep; 2013; 3():1157. PubMed ID: 23362457
[TBL] [Abstract][Full Text] [Related]
38. Progenitor cell mobilization and recruitment: SDF-1, CXCR4, α4-integrin, and c-kit.
Cheng M; Qin G
Prog Mol Biol Transl Sci; 2012; 111():243-64. PubMed ID: 22917234
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
